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Abstract
Background: Recent trials suggest that angiotensin-converting enzyme inhibitors (ACEI) are
effective in prevention of ischemic stroke, as measured by reduced stroke incidence. We aimed to
compare stroke severity between stroke patients who were taking ACEI before their stroke onset
and those who were not, to examine the effects of pretreatment with ACEI on ischemic stroke
severity.
Methods: We retrospectively studied 126 consecutive patients presenting within 24 hours of
ischemic stroke onset, as confirmed by diffusion-weighted magnetic resonance imaging (DWI). We
calculated the NIHSS score at presentation, as the primary measure of clinical stroke severity, and
categorized stroke severity as mild (NIHSS [less than or equal to] 7), moderate (NIHSS 8–13) or
severe (NIHSS [greater than or equal to] 14). We analyzed demographic data, risk-factor profile,
blood pressure (BP) and medications on admissions, and determined stroke mechanism according
to TOAST criteria. We also measured the volumes of admission diffusion- and perfusion-weighted
(DWI /PWI) magnetic resonance imaging lesions, as a secondary measure of ischemic tissue
volume. We compared these variables among patients on ACEI and those who were not.
Results: Thirty- three patients (26%) were on ACE-inhibitors. The overall median baseline NIHSS
score was 5.5 (range 2–21) among ACEI-treated patients vs. 9 (range 1–36) in non-ACEI patients
(p = 0.036). Patients on ACEI prior to their stroke had more mild and less severe strokes, and
smaller DWI and PWI lesion volumes compared to non-ACEI treated patients. However, none of
these differences were significant. Predictably, a higher percentage of patients on ACEI had a
history of heart failure (p = 0.03). Age, time-to-imaging or neurological evaluation, risk-factor
profile, concomitant therapy with lipid lowering, other antihypertensives or antithrombotic agents,
or admission BP were comparable between the two groups.
Conclusion: Our results suggest that ACE-inhibitors may reduce the clinical severity of stroke, as
measured by NIHSS score. Further, larger-scale, prospective studies areneeded to validate our
findings, and to elucidate the mechanism(s) of ACEImediated benefits in patients with ischemic
stroke.
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Background
Data from the heart outcomes prevention evaluation
study (HOPE) suggest that angiotensin-converting
enzyme inhibitors (ACEI) are effective in prevention of
ischemic stroke, as measured by reduced stroke incidence
in subjects randomized to treatment with ACEI [1]. In this
trial, the use of the ACEI, ramipril, resulted in a 32%
reduction in ischemic stroke risk despite minimal reduc-
tion in blood pressure (BP) [1], leading some to suggest
that ACEI may also exert direct neuroprotective effects.
To further elucidate if ACEI have potential neuroprotec-
tive effects, we tested whether their use prior to ischemic
stroke onset might also reduce the severity of stroke. We
examined clinical and admission magnetic resonance
imaging (MRI) data from patients with ischemic stroke to
determine the effects of prestroke use of ACEI on stroke
severity.
Methods
Study design and patient selection
We retrospectively reviewed our prospectively collected
stroke database over a 30-month period from 1998 to
2000, and identified consecutive patients who presented
with acute ischemic stroke within 24 hours of onset and
had DWI/PWI upon presentation. Onset time was
defined, as the last time the patient was known to be in
his/her usual state of health. The diagnosis of ischemic
stroke was confirmed by diffusion-weighted imaging
(DWI) showing evidence of acute cerebral infarction,
combined with serial neurological examinations per-
formed by stroke-trained neurologists. We included
patients who had received thrombolytic, endovascular or
experimental neuroprotective treatment. We only
excluded patients who had transient ischemic attacks
(TIAs), in whom DWI/PWI was negative.
Data collection and assessments
We retrieved the following data for each patient: (1)
demographics; (2) risk factors for stroke, i.e. hypertension
(HTN), diabetes mellitus (DM), hyperlipidemia, coronary
artery disease (CAD), atrial fibrillation (AF), heart failure
(CHF), history of TIA and smoking, as reported by the
patient andhis/her family; (3) vital signs at presentation
(BP and temperature); (4) blood glucose level at admis-
sion; (5) medications upon admission, with particular
attention to antiplatelets, anticoagulants, lipid-lowering
agents, and antihypertensives including ACEI. We did not
collect information about the duration of medication(s)
use, daily use or compliance. Patients and families were
only questioned about patient's use of medication(s),
including ACEI, in the week before stroke; (6) the baseline
National Institute of Health Stroke Scale (NIHSS) score
[2], which was recorded by stroke-trained neurolgistscer-
tified in the application of NIHSS at admission; and (7)
time from strokedetection to imaging.
Outcome measures
We used the NIHSS score at presentation as the primary
measure of clinical stroke severity, and categorized stroke
severity as mild (NIHSS score = 7), moderate (NIHSS
score 8–13) or severe (NIHSS score = 14). We measured
the total DWI and PWI lesion volumes, as secondary radi-
ological measures of stroke severity, in 110/126 patients.
All MRI studies were performed on a Siemens Medical Sys-
tems Vision 1.5-T MR whole body scanner with echopla-
nar imaging capabilities. An experienced researcher
blinded to clinical data and patient's identity, performed
MRI measurements. The volume of the perfusion abnor-
mality was measured on relative Mean Transit Time
(rMTT) maps. The specific MRI sequence parameters,
imaging processing and volumetric analysis are described
in details in previous publications [3,4]. We classified
stroke mechanisms, after completing the diagnostic work-
up, according to the Trial of Org 10172 in Acute Treat-
ment (TOAST) criteria [5].
Statistical analysis
We divided patients into 2 groups, those who were taking
ACEI before their stroke onset and those who were not.
We compared inter-group differences between individual
categorical variables by using student's t-test or Wilcoxon
rank sum test for continuous variables, and Fisher's exact
test forcategorical comparisons, as appropriate. We com-
pared the median baseline NIHSS scores with the Mann-
Whitney U test to evaluate the severity of the stroke in
both groups. The Cochran-Mantel-Haenszel row mean
score rank test, adjusted for various confounding variables
(age, sex, risk factors, use of concomitant medications,
time-from-stroke-to-evaluation, and stroke mechanism/
subtype) was used to control for the differences in NIHSS
scores between ACEI and non-ACEI users. A p-value of <
0.05 was considered statistically significant for all
analyses.
Results
Patient characteristics (demographic and clinical Features)
A total of 126 patients met all of our inclusion and none
of the exclusion criteria, and were included in subsequent
analyses. Approximately, 26% (33 patients) were on ACEI
before stroke onset. Fourteen were taking lisinopril (20 to
40 mg per day), 13 enalapril (10 to 40 mg per day), 5 cap-
topril (75 to 150 mg per day) and 1 accupril (40 mg per
day). None of our patients was taking perindopril or ram-
ipril, or a combination of different ACEI. Table 1 summa-
rizes the demographic and clinical features of patients in
both ACEI- and non ACEI-treated groups. There were no
significant differences in the mean age or sex distribution
between the 2 groups. Slightly higher percentages of ACEI-BMC Neurology 2005, 5:10 http://www.biomedcentral.com/1471-2377/5/10
Page 3 of 7
(page number not for citation purposes)
treated patients had history of HTN, DM, hyperlipidemia,
and smoking in comparison to the non-ACEI group. A
slightly higher percentage of non-ACEI group reported
history of prior TIA. However, none of these differences
were statistically significant. There was a trend towards a
higher frequency of cardiac disease among ACEI-treated
patients. This was mostly driven by a significantly higher
percentage of heart failure among ACEI-treated patients.
A roughly equal percentage of patients in both groups pre-
sented to our emergency room and were imaged within 6
hours from stroke onset (61% in ACEI-treated patients vs.
63% in non-ACEI group; p = 0.83). The mean time from
stroke-symptom onset to evaluation was 10.9+5.2 h in
ACEI-treated patients vs. 11.3+6.4 h in non-ACEI group (p
= 0.62). There were no significant differences in admis-
sion temperature (97+7 F° vs. 98+6 F°; p = 0.34) or glu-
cose levels (137+23 mg/dL vs. 144+29 mg/dL; p = 0.26)
between the 2 groups. The mean SBP upon admission was
162+27 mmHg in ACEI-treated patients vs. 158+31
mmHg in non-ACEI group, and the mean DBP was 84+16
vs. 81+20 mmHg. None of these differences were statisti-
cally significant.
A roughly equal percentage of patients in each group were
using antiplatelets, anticoagulants, statins and other BP
lowering agents. Similarly, the frequency of using other
classes of antihypertensive agents was not significantly
different in either group. Four patients were taking angi-
otensin receptor blockers (ARBs) at the time of their
stroke. None of these 4 patients was on ACEI. They were
all included in non ACEI-treated group for purposes of
statistical analysis.
Patient outcomes
Approximately, 48% of ACEI-treated patients had base-
line NIHSS score = 7 compared with 40% of non-ACEI
group (p = 0.42); 28% had NIHSS score between 8 – 13
vs. 20% in non-ACEI group (p = 0.46); and 24% had
NIHSS score = 14 vs. 40% in non-ACEI users (p = 0.18).
Table 1: Comparison of demographic and clinical features between ACEI- and non ACEI-treated groups.
Number of patients ACEI group 33 (26%) Non-ACEI group 93 (74%) p-value
Sex (women/men) 13/20 43/50
• % women 39% 46% 0.55
• % men 61% 54% 0.55
Mean age (year) ± SD 73 ± 11 70 ± 13 0.23
Risk factors:
History of hypertension 78% 65% 0.19
History of diabetes 32% 24% 0.36
History of hyperlipidemia 28% 22% 0.48
History of cardiac disease 39% 21% 0.06
• CHF 23% 9% 0.03*
• AF 10% 7% 0.69
• CAD 6% 5% 0.98
History of smoking 16% 11% 0.53
History of prior TIA 10% 16% 0.39
Concomitant medications:
Antiplatelets 37% 41% 0.68
Anticoagulants 12% 10% 0.74
Statins 20% 21% 0.99
Other BP lowering agents 56% 52% 0.84
• Diuretics 25% 18% 0.45
• B-blockers 18% 27% 0.35
• Ca++ blockers 13% 13% 0.99
• ARB 0% 4% 0.57
Time from stroke-to evaluation
• 0–6 h 61% 63% 0.83
• 6–25 h 39% 37% 0.83
Clinical features:
NIHSS score, median 5.5 9 0.036*
SBP (mean ± SD), mmHg 162 ± 27 158 ± 31 0.35
DBP (mean ± SD), mmHg 84 ± 16 81 ± 20 0.38
Temperature (mean ± SD), F° 97 ± 7 98 ± 6 0.34BMC Neurology 2005, 5:10 http://www.biomedcentral.com/1471-2377/5/10
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Figure 1 shows the distribution of stroke mechanisms,
according to TOAST criteria, among ACEI- and non ACEI-
treated patients. The stroke mechanisms were roughly
equivalent in both groups. Although, cardioembolic cause
was more frequent among non ACEI-treated patients
(34% vs. 24%) and lacunar etiology was more commonly
seen among patients who were taking ACEI prior to stroke
onset (32% vs. 23%), these differences were not statisti-
cally significant.
The overall median NIHSS score at admission was signifi-
cantly lower in ACEI-treated patients (5.5; range 2 – 21)
than in non-ACEI patients (9; range 1 – 36; p = 0.036).
This difference remained statistically significant after con-
trolling for confounding variables, such as history of
hypertension, TIA, DM hyperlipidemia and cardiac dis-
ease, including CHF, stroke mechanism, onsetto- evalua-
tion time, and concomitant medications, using the
Cochran-Mantel-Haenszel row mean score test using
ranks adjusted for these covariates (p = 0.042). Similarly,
the median NIHSS score at admission was lower in the
ACEI group when the analysis was limited to patients with
non-lacunar strokes (8.5 vs. 12; p = 0.03) or to those who
presented within 6 hours of stroke symptom onset (6 vs.
8; p = 0.046).
The DWI/PWI lesions volumetric measurements were per-
formed in 87% of the patients (110/126). Sixteen patients
were not included in MRI data analyses because their
images were of poor quality to allow adequate
Comparison of stroke mechanisms between ACEI- and non ACEI-treated patients Figure 1
Comparison of stroke mechanisms between ACEI- and non ACEI-treated patients.
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quantitative measurements. As table 2 indicates, there
were no significant differences between both groups with
regard to the mean diffusion, perfusion or perfusion-dif-
fusion (mismatch) lesion volumes.
Discussion
We found that the baseline NIHSS score was lower in
patients who were taking ACEI prior to their stroke com-
pared to those who were not taking ACEI at the time of
stroke onset. The NIHSS is accepted widely for measuring
acute stroke deficits to assess the degree of severity of neu-
rological deficits from stroke and its reliability has been
tested in several clinical trials [6-8].
We found no difference in admission BP between ACEI
and non-ACEI users, suggesting that the beneficial effects
of ACEI use may not be directly related to their BP-lower-
ing effect. This is concordant with the results from the
HOPE trial [1].
Several factors could potentially account for the observed
difference in baseline NIHSS between ACEI and non-ACEI
groups, such as differences in risk factors, stroke mecha-
nism/subtype, or baseline hemodynamic parameters. The
risk factors that influence ACEI use, such as history of
HTN, CHF and DM, were dissimilarly distributed between
the two groups, and their impact on stroke type and sever-
ity cannot be entirely excluded. However, ourfindings are
unlikely to be related to differences in baseline risk factor
profile between the ACEI- and non-ACEI treated patients
since patients who were on ACEI had a higher prevalence
of HTN, DM and heart failure, which may have biased our
data toward higher stroke severity in ACEI-treated
patients, and thus limited our ability to detect larger dif-
ferences in favor of ACEI use. It is possible that ACEI use
reflected a greater degree of medical attention and more
aggressive risk factor reduction in these patients, which
subsequently lessened stroke severity.
Recent studies have shown that TIAs before stroke can
induce tolerance (ischemic preconditioning) to subse-
quent strokes by raising the threshold of brain tissue vul-
nerability, which results in smaller infarct volumes, and
better recovery [9-11]. We found no significant differences
in the frequency of prior history of TIAs, as reported by the
patient or his/her family, between the ACEI and non-ACEI
treated patients. In fact, a slightly higher percentage of
patients in the non-ACEI group reported history of TIAs
prior to their presenting stroke.
Some epidemiological studies show that greater stroke
severity at onset is associated with a shorter interval
between symptom onset and time to emergency depart-
ment arrival [12], suggesting that the observed difference
in baseline NIHSS could be attributed to dissimilar distri-
bution of patients' arrival time to the hospital. However,
a roughly identical proportion of patients in both groups
presented to our hospital within 6 hours of stroke-symp-
tom onset.
Since the observed beneficial effect of ACEI on stroke
severity could potentially be secondary to ACEI effects on
stroke mechanism, we examined the impact of ACEI use
on stroke mechanism using TOAST criteria. We found a
greater preponderance of lacunar strokes among ACEI-
treated patients and cardioembolic strokes among non-
ACEI patients. However, these differences were not signif-
icant and the difference in baseline NIHSSS remained sig-
nificant even after excluding patients with non-lacunar
strokes from analysis. This suggests that ACEI use did not
seem to influence stroke mechanism in our cohort of
patients, and that our findings were unrelated to the
higher frequency of lacunar strokes among ACEI-treated
patients. Similarly, the beneficial effect of ACEI in our
patients is unlikely to be related to other concomitant
treatments. Although, several patients in both groups
were on statins, antithrombotics and other antihyperten-
sive agents, we found no significant difference between
ACEI- and non ACEI-treated patients receiving any of
these classes of drugs. Finally, it is noteworthy that the dif-
ference in baseline stroke severity between ACEI and non-
ACEI groups remained statistically significant after adjust-
ing for the above confounding variables.
A recent prospective observational study of 507 patients
with first-ever ischemic stroke showed that treatment with
ACEI at the time of stroke onset is associated with reduced
plasma concentration of C-reactive protein and better
long-term outcomes [13], suggesting that ACEI may have
anti-inflammatory properties and reduce the acute-phase
inflammatory response after stroke onset. There are sev-
eral other potential mechanisms by which ACEI may pro-
Table 2: Comparison of MRI between ACEI- and non ACEI-treated group
ACEI group Non-ACEI group p-value
DWI lesion volume (mean ± SD), cm3 25.2 ± 23.4 28.7 ± 25.0 0.55
PWI lesion volume (mean ± SD), cm3 72.6 ± 56.6 75.1 ± 68.5 0.86
Mismatch (PWI – DWI) volume 47.6 ± 39.5 46.6 ± 28.2 0.93BMC Neurology 2005, 5:10 http://www.biomedcentral.com/1471-2377/5/10
Page 6 of 7
(page number not for citation purposes)
vide benefit to stroke patients. Experimental data suggest
that the rennin angiotensin system modulates the athero-
sclerotic process, and that angiotensin II exerts pro-
inflammatory actions in the vascular wall, which induce
the production of reactive oxygen species and hydroxyl
radicals, cytokines and adhesion molecules [14-19]. Angi-
otensin converting enzyme inhibitors could provide neu-
roprotection via blockade of angiotensin II-mediated
endothelial dysfunction, lipid peroxidation and subse-
quent oxidative stress, and vascular smooth muscle intra-
cellular calcium accumulation and hypertrophy [14-20].
Furthermore, ACEI may help maintain homeostatic bal-
ance of fibrinolytic and procoagulant factors [21] and
increase cerebral blood flow [22]. Recent studies using
transcranial Doppler ultrasonography have shown that
perindopril can improve the cerebral vasomotor reactivity
in patients with lacunar infarcts beyond any effect on BP
[22], and that treatment with quinapril can ameliorate
cerebrovascular reactivity caused by methionine-induced
hyperhomocysteinemia in healthy volunteers [23].
We found that ACE I use had no effect on MRI measures
of ischemic lesion volume. This discrepancy between the
beneficial effects of ACEI on clinical, but not radiological,
measures of stroke severity is reconcilable since the corre-
lation between infarct volume and NIHSS is only moder-
ate, particularly in non-dominant hemispheric strokes
[24-26]. We explored the possibility that the lower NIHSS
scores in ACEI-treated patients might be secondary to a
higher percentage of non-dominant hemispheric strokes
in this group [26]. However, we found no significant dif-
ference in the preponderance of non-dominant hemi-
spheric strokes between the 2 groups (data not reported).
Infarct location, not only size, is also an important deter-
minant of the severity of clinical deficits and our small
sample size may have limited our ability to detect a differ-
ence in favor of ACEI.
We acknowledge that our study has inherent limitations
imposed by its retrospective nature, non-randomization
of treatment allocation and small sample size. The small
number of ACEI-treated patients does not allow us to test
for possible differences among the various ACEIs or dose
regimens. Similarly, we cannot be certain of the duration
of treatment or compliance with daily use of ACEI in our
patients. We used an arbitrary cut-off for NIHSS scores to
categorize stroke severity. It is possible that different cut-
off values could lead to different results. Most impor-
tantly, our study lacks follow-up data regarding the effect
of ACEI use on long-term outcomes since a large percent-
age of our patients were either enrolled in experimental
neuroprotective trials or treated with thrombolysis upon
presentation.
Conclusion
Our results show that pre-stroke use of ACEI is associated
with milder stroke severity, as assessed by NIHSS score.
Our findings need to be prospectively validated in larger-
scale randomised studies, and the mechanism(s) of ACEI-
mediated benefits in patients with ischemic stroke need to
be elucidated.
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